|
1
|
Kim N, Sun HY, Youn MY and Yoo JY:
IL-1β-specific recruitment of GCN5 histone acetyltransferase
induces the release of PAF1 from chromatin for the de-repression of
inflammatory response genes. Nucleic Acids Res. 41:4495–4506. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grabiec AM, Tak PP and Reedquist KA:
Targeting histone deacetylase activity in rheumatoid arthritis and
asthma as prototypes of inflammatory disease: Should we keep our
HATs on? Arthritis Res Ther. 10:2262008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grausenburger R, Bilic I, Boucheron N,
Zupkovitz G, El-Housseiny L, Tschismarov R, Zhang Y, Rembold M,
Gaisberger M, Hartl A, et al: Conditional deletion of histone
deacetylase 1 in T cells leads to enhanced airway inflammation and
increased Th2 cytokine production. J Immunol. 185:3489–3497. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roger T, Lugrin J, Le Roy D, Goy G,
Mombelli M, Koessler T, Ding XC, Chanson AL, Reymond MK, Miconnet
I, et al: Histone deacetylase inhibitors impair innate immune
responses to Toll-like receptor agonists and to infection. Blood.
117:1205–1217. 2011. View Article : Google Scholar
|
|
5
|
Katto J, Engel N, Abbas W, Herbein G and
Mahlknecht U: Transcription factor NFkB regulates the expression of
the histone deacetylase SIRT1. Clin Epigenetics. 5:112013.
View Article : Google Scholar
|
|
6
|
Blanchard F and Chipoy C: Histone
deacetylase inhibitors: New drugs for the treatment of inflammatory
diseases? Drug Discov Today. 10:197–204. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT
and Kim DY: Trichostatin A attenuates airway inflammation in mouse
asthma model. Clin Exp Allergy. 35:89–96. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Toussirot E, Wendling D and Herbein G:
CIC-1431: Biological treatments given in patients with rheumatoid
arthritis or ankylosing spondylitis modify HAT/HDAC (histone
acetyl-transferase/histone deacetylase) balance. Joint Bone Spine.
81:544–545. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gillespie J, Savic S, Wong C, Hempshall A,
Inman M, Emery P, Grigg R and McDermott MF: Histone deacetylases
are dysregulated in rheumatoid arthritis and a novel histone
deacetylase 3-selective inhibitor reduces interleukin-6 production
by peripheral blood mononuclear cells from rheumatoid arthritis
patients. Arthritis Rheum. 64:418–422. 2012. View Article : Google Scholar
|
|
10
|
Strietholt S, Maurer B, Peters MA, Pap T
and Gay S: Epigenetic modifications in rheumatoid arthritis.
Arthritis Res Ther. 10:2192008. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang CR, Shih KS, Liou JP, Wu YW, Hsieh
IN, Lee HY, Lin TC and Wang JH: Denbinobin upregulates miR-146a
expression and attenuates IL-1β-induced upregulation of ICAM-1 and
VCAM-1 expressions in osteoarthritis fibroblast-like synoviocytes.
J Mol Med (Berl). 2014.Epub ahead of print. View Article : Google Scholar
|
|
12
|
Lu MC, Yu CL, Chen HC, Yu HC, Huang HB and
Lai NS: Increased miR-223 expression in T cells from patients with
rheumatoid arthritis leads to decreased insulin-like growth
factor-1-mediated interleukin-10 production. Clin Exp Immunol.
177:641–651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fulci V, Scappucci G, Sebastiani GD,
Giannitti C, Franceschini D, Meloni F, Colombo T, Citarella F,
Barnaba V, Minisola G, et al: miR-223 is overexpressed in
T-lymphocytes of patients affected by rheumatoid arthritis. Hum
Immunol. 71:206–211. 2010. View Article : Google Scholar
|
|
14
|
Pauley KM, Satoh M, Chan AL, Bubb MR,
Reeves WH and Chan EK: Upregulated miR-146a expression in
peripheral blood mononuclear cells from rheumatoid arthritis
patients. Arthritis Res Ther. 10:R1012008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu S, Pan W, Song X, Liu Y, Shao X, Tang
Y, Liang D, He D, Wang H, Liu W, et al: The microRNA miR-23b
suppresses IL-17-associated autoimmune inflammation by targeting
TAB2, TAB3 and IKK-α. Nat Med. 18:1077–1086. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lai NS, Yu HC, Chen HC, Yu CL, Huang HB
and Lu MC: Aberrant expression of microRNAs in T cells from
patients with ankylosing spondylitis contributes to the
immunopathogenesis. Clin Exp Immunol. 173:47–57. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meng S, Cao J, Zhang X, Fan Y, Fang L,
Wang C, Lv Z, Fu D and Li Y: Downregulation of microRNA-130a
contributes to endothelial progenitor cell dysfunction in diabetic
patients via its target Runx3. PloS One. 8:e686112013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li S, Duan X, Li Y, Liu B, McGilvray I and
Chen L: MicroRNA-130a inhibits HCV replication by restoring the
innate immune response. J Viral Hepat. 21:121–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Osbourne A, Calway T, Broman M, McSharry
S, Earley J and Kim GH: Downregulation of connexin43 by
microRNA-130a in cardiomyocytes results in cardiac arrhythmias. J
Mol Cell Cardiol. 74:53–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim GH, Samant SA, Earley JU and Svensson
EC: Translational control of FOG-2 expression in cardiomyocytes by
microRNA-130a. PloS One. 4:e61612009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Chen X, Lin J, Lwin T, Wright G,
Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E and Tao J:
Myc represses miR-15a/miR-16-1 expression through recruitment of
HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.
Oncogene. 31:3002–3008. 2012. View Article : Google Scholar
|
|
22
|
Kim Y, Kim H, Park H, Park D, Lee H, Lee
YS, Choe J, Kim YM and Jeoung D: miR-326-histone deacetylase-3
feedback loop regulates the invasion and tumorigenic and angiogenic
response to anti-cancer drugs. J Biol Chem. 289:28019–28039. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang J, Kalkum M, Chait BT and Roeder RG:
The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the
JNK pathway through the integral subunit GPS2. Mol Cell. 9:611–623.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bendinelli P, Matteucci E, Maroni P and
Desiderio MA: NF-kappaB activation, dependent on
acetylation/deacetylation, contributes to HIF-1 activity and
migration of bone metastatic breast carcinoma cells. Mol Cancer
Res. 7:1328–1341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mahlknecht U, Will J, Varin A, Hoelzer D
and Herbein G: Histone deacetylase 3, a class I histone
deacetylase, suppresses MAPK11-mediated activating transcription
factor-2 activation and represses TNF gene expression. J Immunol.
173:3979–3990. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han KA, Kang HS, Lee JW, Yoo L, Im E, Hong
A, Lee YJ, Shin WH and Chung KC: Histone deacetylase 3 Promotes
RCAN1 Stability and nuclear translocation. PloS One. 9:e1054162014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fabbroni M, Cantarini L, Caso F, Costa L,
Pagano VA, Frediani B, Manganelli S and Galeazzi M: Drug retention
rates and treatment discontinuation among anti-TNF-α agents in
psoriatic arthritis and ankylosing spondylitis in clinical
practice. 2014:8629692014.
|
|
28
|
Fenix-Caballero S, Alegre-del Rey EJ,
Castaño-Lara R, Puigventós-Latorre F, Borrero-Rubio JM and
López-Vallejo JF: Direct and indirect comparison of the efficacy
and safety of adalimumab, etanercept, infliximab and golimumab in
psoriatic arthritis. J Clin Pharm Ther. 38:286–293. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Costa L, Caso F, Atteno M, Del Puente A,
Darda MA, Caso P, Ortolan A, Fiocco U, Ramonda R, Punzi L and
Scarpa R: Impact of 24-month treatment with etanercept, adalimumab,
or methotrexate on metabolic syndrome components in a cohort of 210
psoriatic arthritis patients. Clin Rheumatol. 33:833–839. 2014.
|
